Anthony Cecchini, Mba, Msf Email and Phone Number

• Actively managed transition to GAAP and restatement of prior period financials, and restructuring of financial reporting and forecasting process to effectively integrate three overlapping corporate entities to achieve better clarity of performance across the organization.• Developed KPI dashboards and other operational reporting packages for the company’s leadership team, board of directors, and investors.• Managed configuration and rollout of a new EMR to standardize data collection across entities, improve reporting, and ensure greater compliance with insurance regulations.• Ensured the company was in compliance with various financial and non-financial agreements, including government contracts and grants, and lending facilities.Accomplishments• Structured and managed a $7.5mn credit facility to fund the company’s growth strategy and actively manage working capital requirements.

• Oversaw day-to-day operations of the accounting, treasury, FP&A, payroll, tax, and risk management functions, and managed the company’s external bookkeeper.• Developed and actively managed the 2019 budget and five-year operational plan, used as the basis for investment decisions, in coordination with the CEO, COO, and other internal and external key stakeholders.• Prepared weekly, monthly and quarterly budget and operational reporting packages for the company’s leadership team, board of directors, and investors.• Managed the company’s 2018 restatement and transition from cash to accrual accounting in anticipation of a 2019 audit and Series B fundraising.Accomplishments• Secured initial equity investment of $4mn, from a group of investors consisting of healthcare payors and social impact investment funds, to fund the company’s growth strategy.

• Developed 2017 and 2018 forecast, and implemented a formalized annual budget and interim review process. Additionally, developed cash flow forecasting process to allow for improved liquidity management and used as the basis for planning growth and capital expenditures.• Created key performance indicator (KPI) reporting system, used as the basis for identifying opportunities for growth, allocating employee and investment resources, and tracking company performance against key benchmarks.• Conducted market research and developed competitive intelligence reports to identify attractive markets for investment and acquisition targets.Accomplishments• Secured equity investment of $5mn to fund the company’s acquisition growth strategy and working capital expenditures.

• Managed the annual and multi-year budget forecast for the company's international operations, conducted due diligence on potential acquisitions and greenfield projects, and actively managed the company’s foreign currency exposure and hedging portfolio.• Responsible for ensuring compliance with the company’s Credit Agreement / Indenture.• Oversaw cash flow forecasting process, including daily and 26-week cash flow forecasts, to allow for improved liquidity management and used as the basis for deal negotiation, the setting of financial covenants, and capital expenditure planning.• Managed the company’s capital and operating lease portfolio, including negotiating new lease transactions and end-of-lease buyouts.• Prepared financial reports, presentations, marketing materials, and transaction-related documentation for Executive Management, the Board of Directors, and investors.• Prepared required reporting schedules pertaining to treasury, including bank financing, derivatives and debt disclosures, and international finance for the company’s SEC filings.• Performed industry and competitive analyses. Researched and analyzed corporate development opportunities, including necessary capital outlay, funding strategies, operational impact, and projected return on investment.• Drafted press releases and management conference call scripts, and responded to investor inquiries.Accomplishments• Structured more than $2bn of financing transactions, including: o A $610mn Term Facility, an up to $125mn Revolving Credit Facility, and a $360mn Senior Unsecured Notes offering to restructure the company’s capital structure and support the company’s growth strategy. o A $385mn Preferred Equity financing to provide substantial incremental liquidity, enabling significant debt reduction and securing long-term capital necessary to support the company’s growth strategy.

• Launched coverage of 17 companies in the specialty pharmaceutical and biotechnology industries. Constructed comprehensive market, financial, and valuation models – using numerous data sources – that served as the basis for long and short investment recommendations focused on binary events.Accomplishments• Achieved credibility for a new sell-side research brand among buy-side clients by making successful out-of-consensus investment recommendations on Salix Pharmaceuticals (SLPX) in March 2011 and The Medicines Company (MDCO) in August 2011.

• Constructed financial models – assuming a variety of financing scenarios – used as the basis for deal negotiation, the setting of financial covenants, and development of the annual budget and five-year plan. Performed cash flow analyses based on proposed deal structures, and maintained the daily and 13-week cash flow forecasts.• Overhauled process for tracking and analyzing facility-level census, resulting in more precise budgets and forecasts.• Performed industry and competitive analyses. Researched and analyzed corporate development opportunities, including necessary capital outlay, funding strategies, operational impact, and projected return on investment.Accomplishments• Supported closing of a $235mn secured debt financing.

• Published in-depth research reports covering the industry’s competitive landscape, legislative and regulatory issues, patent litigation, prescription trends, therapeutic substitution, generic market opportunities, and mergers and acquisitions activity.• Gathered and analyzed prescription data from IMS and Wolters Kluwer PHAST, and market data from the FDA, Bloomberg, and other third-party sources. Interviewed key opinion leaders (KOLs) and surveyed physicians at industry conferences.Accomplishments• Achieved credibility for a new sell-side research team by generating proprietary research reports and making successful out-of-consensus investment recommendations, including ViroPharma (VPHM) in September 2009.

• Generated research reports focused on actionable investment ideas and binary events. Interviewed KOLs at industry conferences and reported industry trends. Acquired access to senior management of covered and non-covered companies.Accomplishments• Achieved recognition as a key player on a team ranked 4th in the Biotechnology sector according to the 2008 Wall Street Journal “Best on the Street” analyst survey.• Generated alpha for institutional investor clients and achieved personal notoriety as savvy analyst by making highly successful, out-of-consensus investment recommendations on Biogen Idec (BIIB) in December 2007 and Elan (ELN) in June 2008.

• Acquired deep understanding of the branded and generic drug industry, and leveraged that knowledge to make a greater impact for the group via direct contributions to research content.• Developed proprietary databases that identified key market drivers and trends, including branded and generic drug approval trends, therapeutic substitution, and generic market penetration.Accomplishments• Ranked as the #1 Junior Analyst by firm’s institutional sales force in 2006.• Contributed key expertise to the team that propelled the Senior Analyst to the #1 ranking in the Annual Institutional Investor Sell-Side Analyst Survey.

• Supported Chief Financial Officer by generating monthly, quarterly, and annual financial reports. Performed industry and competitive analysis, developed department budgets, tracked progression of ongoing development projects and contract revenues earned for accruals, and prepared reports for presentation to Chief Executive Officer, Chief Financial Officer and the Board of Directors.Accomplishments• Performed industry and competitive analysis in order to value the company relative to industry peers and identify potential acquisition candidates. Presented results to Chief Executive Officer, Chief Financial Officer and the Board of Directors. • Supported implementation of new accounting system, including evaluation, selection and customization the new system, and the porting of data from the legacy system.